RedHill Biopharma (RDHL) Finished Goods (2017 - 2024)

RedHill Biopharma (RDHL) has 8 years of Finished Goods data on file, last reported at $2.8 million in Q4 2024.

• On a quarterly basis, Finished Goods fell 14.96% year-over-year to $2.8 million in Q4 2024; TTM through Dec 2024 was $2.8 million, a 14.96% decrease from a year earlier, with the FY2024 full-year figure at $2.8 million, down 14.96% from the prior year.
• Finished Goods for Q4 2024 stood at $2.8 million, down from $3.3 million in the prior quarter.
• Over the last five years, Finished Goods for RDHL reached as high as $6.8 million in Q4 2022 and fell as low as $2.8 million in Q4 2024.
• Historically, Finished Goods has averaged $4.9 million across 5 years, with a median of $4.7 million in 2020.
• Across the five-year window, Finished Goods jumped 1521.23% in 2020 and slumped 51.25% in 2023, its largest moves.
• Year by year, Finished Goods stood at $4.7 million in 2020, then soared by 39.48% to $6.6 million in 2021, then grew by 3.39% to $6.8 million in 2022, then slumped by 51.25% to $3.3 million in 2023, then dropped by 14.96% to $2.8 million in 2024.
• Per Business Quant data, the three most recent Finished Goods figures were $2.8 million in Q4 2024, $3.3 million in Q4 2023, and $6.8 million in Q4 2022.